| Type: | combo |
| Component1: | Lamivudine |
| Class1: | nucleoside reverse transcriptase inhibitor |
| Component2: | Nevirapine |
| Class2: | non-nucleoside reverse transcriptase inhibitor |
| Component3: | Zidovudine |
| Class3: | nucleoside reverse transcriptase inhibitor |
| Tradename: | Duovir-N, Zidovex-LN, others |
| Cas Number: | 1256374-17-0 |
| Atc Prefix: | J05 |
| Atc Suffix: | AR05 |
| Chemspiderid: | none |
Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains lamivudine, nevirapine, and zidovudine. It is either used by itself or along with other antiretrovirals. It is a recommended treatment in those who are pregnant. It is taken by mouth twice a day.[1]
The medication is generally well tolerated.[2] Side effects are those of the underlying medications.[1] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.[2] Use is not recommended in those with significant liver problems.[2] Use in pregnancy and breastfeeding appear to be safe.[2] The combination tablet is typically not appropriate for children.[1]
It is on the World Health Organization's List of Essential Medicines.[3] The combination is not commercially available in the United States as of 2018.[4]